H.C. Wainwright reiterates a Buy rating on MannKind (MNKD) with an $11 price target after the company provided a 2026 business update. The firm is positive on MannKind’s outlook over the next two years, saying “very little value is ascribed to the multiple tailwinds that could be validated in 2026.” The FDA decision on Afrezz’s label update concerning dose conversion for mealtime insulin switching is on January 23, and a separate application for pediatric use in type 1/2 diabetes has a May 29 action date, the analyst tells investors in a research note.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MNKD:
- MannKind provides business updates, 2026 growth drivers
- 3 ‘Strong Buy’ Stocks to Buy Today,12/24/2025, According to Top Analysts
- MannKind announes FDA approval of sNDA for FUROSCIX On-body Infusor
- MannKind’s Clofazimine Inhalation Study Terminated: Implications for Investors
- MannKind says FDA accepts for review its sNDA of of FUROSCIX ReadyFlow